Trials / Completed
CompletedNCT05134337
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
A Phase 1, Open Label, Two-part, Fixed-sequence Drug Interaction Study to Investigate the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and CYP3A4 Inducer (Rifampin) on the Pharmacokinetics of LOXO 305 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Loxo Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LOXO-305 | Oral LOXO-305 |
| DRUG | Itraconazole | Oral itraconazole |
| DRUG | Rifampin | Oral rifampin |
Timeline
- Start date
- 2020-02-12
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
- First posted
- 2021-11-24
- Last updated
- 2025-01-09
- Results posted
- 2025-01-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05134337. Inclusion in this directory is not an endorsement.